Influence of lipids and obesity on haemorheological parameters in patients with deep vein thrombosis

Amparo Vayá; Cristina Falcó; María Simó; Fernando Ferrando; Yolanda Mira; José Todolí; Francisco España; Dolores Corella

doi:10.1160/TH07-02-0095

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 98(03): 621-626
DOI: 10.1160/TH07-02-0095

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Influence of lipids and obesity on haemorheological parameters in patients with deep vein thrombosis

Amparo Vayá

¹Haemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital, Valencia, Spain

,

Cristina Falcó

¹Haemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital, Valencia, Spain

,

María Simó

¹Haemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital, Valencia, Spain

,

Fernando Ferrando

¹Haemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital, Valencia, Spain

,

Yolanda Mira

¹Haemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital, Valencia, Spain

,

José Todolí

²Internal Medicine Service, La Fe University Hospital, Valencia, Spain

,

Francisco España

³Research Centre, La Fe University Hospital, Valencia, Spain

,

Dolores Corella

⁴Genetic and Molecular Epidemiology Unit, School of Medicine, University of Valencia, Spain

⁵CIBER Fisiopatología de la obesidad y nutrición, Instituto de Salud Carlos III, Madrid, Spain

› Author Affiliations

Abstract

Summary

It is not well established whether haemorheological alterations constitute independent risk factors for deep vein thrombosis (DVT).We have determined in 149 DVT patients and in 185 control subjects the body mass index (BMI), the haemorheological profile: blood viscosity (BV), plasma viscosity (PV), fibrinogen (Fg), erythrocyte aggregation (EA), erythrocyte deformability (ED) and plasma lipids. In the crude analysis BMI, Fg, PV, EA, triglycerides (TG) and ApoB were statistically higher and HDL cholesterol (HDL-Chol) statistically lower in DVT patients than in controls. No differences in BV and ED were observed. After BMI adjustment, Fg, PV and EA remained statistically higher in DVT cases than in controls (P=0.013; P=0.012; P=0.013; P=0.028, respectively). When the risk of DVT associated with these variables (using cut-offs that corresponded to the mean plus one SD of the control group) was estimated, EA>8.2 and PV>1.28 mPa·s were significantly associated with DVT even further adjustment for lipids and obesity (OR=2.78, P=0.004; OR=1.91, P=0.024, respectively). However, PV did not remain statistically significant after additional adjustment for Fg. When we consider together all the analyzed variables in order to control every variable for each other, TG>175 mg/dl (OR=3,2,P=0.004) and BMI>30 kg/m² (OR=3.5, P=0.003), were also independently associated with a greater risk of DVT. Our results suggest that increased EA constitute an independent risk factor for DVT. However, when associated to hyperlipidaemia and obesity it further increases thrombotic risk.

Keywords

Deep vein thrombosis - lipids - obesity - haemorheology

Full Text

References

References
1 Rosendaal FR. Venous thrombosis: a multicausal disease. The Lancet 1999; 353: 1167-1173.
2 Virchow R. Thrombose und Embolie (1846–1856). Verlag-von Johann Ambrosius Barth; Leipzig, Germany: 1910
3 Lowe GDO. Thrombosis and hemorheology. In: Clinical Hemorheology. Dordrecht/Boston: Martinus Nijhoff Publishers; 1987: 195-226.
4 Lowe GDO. Rheological influences on thrombosis. Baillieres Clin Haematol 1994; 7: 573-589.
5 Balendra R, Rumlev A, Orr M. et al. Blood lipids, coagulation, fibrinolysis and rheology in spontaneous proven deep vein thrombosis. Brit J Haematol 1991; 77 (Suppl. 01) 83 Abstract.
6 Koppensteiner R, Hofmann S, Atteneder M. et al. Blood rheology in acute deep venous thrombosis. Follow up to one year after the acute event under conventional anticoagulant treatment. Clin Hemorheol 1992; 12: 495 Abstract.
7 Chabanel A, Horellou H, Conard J. et al. Red blood cell aggregability in patients with a history of leg vein thrombosis: influence of post-thrombotic treatment. Brit J Haematol 1994; 88: 174-179.
8 Koster T, Rosendaal FR, Reitsma PH. et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-722.
9 Mira Y, Vayá A, Martínez M. et al. Hemorheological alterations and hypercoagulable state in deep vein thrombosis. Clin Hemorheol Microcirc 1998; 19: 265-270.
10 Vaya A, Mira Y, Martinez M. et al. Biological risk factors for deep vein thrombosis. Clin Hemorheol Microcirc 2002; 26: 41-53.
11 Alt E, Banyai S, Banyai M. et al. Blood rheology in deep venous trombosis--relation to persistent and transient risk factors. Thromb Res 2002; 107: 101-107.
12 Krieger E, van Der Loo B, Amann-Vesti BR. et al. C-reactive protein and red cell aggregation correlate with late venous function after acute deep venous thrombosis. J Vasc Surg 2004; 40: 644-649.
13 Hansson PO, Eriksson H, Welin L. et al. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: "the study of men born in 1913". Arch Intern Med 1999; 159: 1886-1890.
14 Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415-3420.
15 Tsai AW, Cushman M, Rosamond WD. et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182-1189.
16 Vaya A, Mira Y, Ferrando F. et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002; 118: 255-259.
17 Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493-498.
18 Fuchs S, Heyse T, Rudofsky G. et al. Continuous passive motion in the prevention of deep-vein thrombosis: a randomised comparison in trauma patients. J Bone Joint Surg Br 2005; 87: 1117-1122.
19 Cogo A, Bernardi E, Prandoni P. et al. Acquired risk factors for deep vein thrombosis in symptomatic outpatients. Arch Intern Med 1994; 154: 164-168.
20 Kawasaki T, Kambayashi J, Ariyoshi H. et al. Hypercholesterolemia as a risk factor for deep vein thrombosis. Thromb Res 1997; 88: 67-73.
21 McColl MD, Sattar N, Ellison J. et al. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagul Fibrinolysis 2000; 11: 225-229.
22 Griffin JH, Fernández JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001; 86: 386-394.
23 Gónzalez-Ordóñez AJ, Fernández-Carreira JM, Fernández-Alvarez CR. et al. The concentrations of soluble vascular cell adhesion molecule-1 and lipids are independently associated with venous thromboembolism. Haematologica 2003; 88: 1035-1043.
24 Doggen CJM, Smith NL, Lemaitre RZ. et al. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 1970-1975.
25 Deguchi H, Pecheniuk NM, Elias DJ. et al. Highdensity lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112: 893-899.
26 Ageno W, Prandoni P, Romualdi E. et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006; 4: 1914-1918.
27 Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol 1996; 143: 1257-1265.
28 Guidelines for measurement of blood viscosisty and erythrocyte deformability. International Committee for standarization in Haematology, Expert panel on blood rheology. Clin Hemorheol 1986; 6: 439-453.
29 Jung F, Roggenkamp HG, Schneider R. et al. Das Kapillarschlauch-Plasmaviskosimeter. Ein neues Messgerät zur Quantifizierung der Blutplasmaviskosität. Biomed Tech 1983; 28: 249-252.
30 Schmid-Schönbein H, Volger E, Teitel P. et al. New hemorheological techniques for the routine laboratory. Clin Hemorheol 1983; 2: 93-105.
31 Ruef P, Pöschl JMB. Linderkamp. The rheodyn SSD for measuring erythrocyte deformability. Biorheology 1995; 32: 357-358.
32 Mira Y, Vayá A, Martínez M. et al. Effect of unfractionated sodium heparin at therapeutic doses on the hemorheological parameters of patients with deep vein thrombosis. Clin Hemorheol 1996; 16: 277-284.
33 Da Silva MA, Cardoso L, Geraldes J. et al. Haemorheological and coagulation conditions in patients with acute deep venous thrombosis compared with subjects without vascular disease. Clin Hemorheol 1991; 11: 534 Abstract.
34 Kenny MW, Meakin M, Stuart J. Methods for removal of leucocytes and platelets prior to study of erythrocyte deformability. Clin Hemorheol 1983; 3: 191-200.
35 Stuart J, Stone PCW, Bareford D. et al. Evaluation of leucocyte removal methods for studies of erythrocyte deformability. Clin Hemorheol 1985; 5: 137-147.
36 Razavian SM, Atger V, Giral M. et al. Influence of HDL subfractions on erythrocyte aggregation in hypercholesterolemia men. Artherioscl Thromb 1994; 14: 361-366.
37 Ruhenstroth-Bauer G, Hossmer G, Ottl J. et al. Highly significant negative correlations between erythrocyte aggregation value and serum value concentration of high density lipoprotein cholesterol in a sample from a normal population and in patients with coronary heart disease. European Journal of Clinical Investigation 1987; 17: 275-279.
38 Vayá A, Martínez M, Carmena R. et al. Red blood cell aggregation and primary hyperlipoproteinemia. Thromb Res 1993; 72: 119-126.
39 Koenig W, Sund M, Ernst E. et al. Association between rheology and components of lipoproteins in human blood. Circulation 1992; 85: 2197-2204.
40 Falcó C, Vayá A, Simó M. et al. Influence of fibrinogen levels on erythrocyte aggregation determined with the Myrenne aggregometer and the Sefam erythro- aggregometer. Clin Hemorheol Microcirc 2005; 33: 145-151.
41 Weng X, Roederer GO, Beaulieu R. et al. Contribution of acute-phase proteins and cardiovascular risk factors to erythrocyte aggregation in normolipidaemic and hyperlipidaemic individuals. Thromb Haemost 1998; 80: 903-908.
42 Vayá A, Falcó C, Réganon E. et al. Influence of plasma and erythrocyte factors on red blood cell aggregation in survivors of acute myocardial infarction. Thromb Haemost 2004; 91: 354-359.
43 Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660.
44 Margaglione M, Cappucci G, d’Addedda M. et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998; 18: 562-567.
45 Woodward M, Lowe GDO, Rumley A. et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow Monica Survey II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. British Journal of Haematology 1997; 97: 785-797.
46 Goodman E, Dolan LM, Morrison JA. et al. Factor analysis of clustered cardiovascular risks in adolescence: obesity is the predominant correlate of risk among youth. Circulation 2005; 19: 1970-1977.